Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 54Breast Neoplasms 37Fallopian Tube Neoplasms 22Multiple Myeloma 19Carcinoma, Ovarian Epithelial 15Neoplasms 12Lymphoma 10Triple Negative Breast Neoplasms 7Neoplasm Metastasis 6Lymphoma, Large B-Cell, Diffuse 6Recurrence 5Hodgkin Disease 4Breast Neoplasms, Male 4Solid Tumors 3Prostatic Neoplasms 3Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Anaplastic 3Burkitt Lymphoma 3Sarcoma, Kaposi 2Sarcoma 2Peritoneal Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2

Interventions

parsaclisib 2MLN 8237 2zanidatamab 1tislelizumab 1tanespimycin 1spartalizumab 1sitravatinib 1pembrolizumab 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1cabiralizumab 1Temozolomide 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1HMPL-013 1Capecitabine 1AZD7648 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignancies × liposomal doxorubicin × Clear all
NCT03907969 2024-02-06

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

AstraZeneca

Phase 1/2 Completed
30 enrolled 17 charts

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡